亚虹医药-U
(688176)
| 流通市值：53.81亿 | | | 总市值：70.54亿 |
| 流通股本：4.36亿 | | | 总股本：5.71亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 130,237,475.13 | 61,101,125.72 | 201,562,432.59 | 138,951,629.03 |
| 营业收入 | 130,237,475.13 | 61,101,125.72 | 201,562,432.59 | 138,951,629.03 |
| 二、营业总成本 | 315,289,508.12 | 152,883,339.26 | 609,000,649.86 | 422,331,119.09 |
| 营业成本 | 34,946,349.17 | 12,910,056.67 | 49,301,700.81 | 28,572,333.59 |
| 税金及附加 | 1,129,132.21 | 380,047.49 | 1,278,383.16 | 889,515.47 |
| 销售费用 | 113,233,639.3 | 61,368,025.34 | 185,492,997.71 | 131,694,373.01 |
| 管理费用 | 44,263,623.66 | 21,100,052.43 | 77,256,318.82 | 57,774,514.76 |
| 研发费用 | 116,488,982.05 | 55,061,232.76 | 311,915,236.53 | 219,040,308.86 |
| 财务费用 | 5,227,781.73 | 2,063,924.57 | -16,243,987.17 | -15,639,926.6 |
| 其中:利息费用 | 6,089,331.47 | 2,264,677.22 | 6,754,468.09 | 5,031,291.88 |
| 其中:利息收入 | 2,096,169.55 | 766,153.06 | 23,917,227.2 | 23,222,009.91 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,257,657.52 | 1,094,239.72 | 9,722,711.24 | 7,618,197.54 |
| 加:投资收益 | 13,082,697.49 | 5,394,673.34 | 14,732,400.95 | 10,197,494.81 |
| 资产处置收益 | 205.5 | 205.5 | 45,298.45 | 45,298.45 |
| 资产减值损失(新) | 24,283.46 | 581.14 | -1,013,748.59 | -914,953.96 |
| 信用减值损失(新) | -1,343,055.01 | -1,041,572.56 | -4,511,928.44 | -3,441,432.62 |
| 其他收益 | 2,531,836.13 | 614,608.56 | 4,657,540.07 | 1,214,903.92 |
| 四、营业利润 | -167,498,407.9 | -85,719,477.84 | -383,805,943.59 | -268,659,981.92 |
| 加:营业外收入 | - | - | 800 | 800 |
| 减:营业外支出 | 3,035,785.58 | 671,764.89 | 2,990,683.29 | 2,898,340.4 |
| 五、利润总额 | -170,534,193.48 | -86,391,242.73 | -386,795,826.88 | -271,557,522.32 |
| 减:所得税费用 | -521,979.17 | -49,563.51 | -795,767.21 | -215,451.38 |
| 六、净利润 | -170,012,214.31 | -86,341,679.22 | -386,000,059.67 | -271,342,070.94 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -170,012,214.31 | -86,341,679.22 | -386,000,059.67 | -271,342,070.94 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -162,214,047.61 | -83,530,738.28 | -384,063,418.64 | -270,840,063.46 |
| 少数股东损益 | -7,798,166.7 | -2,810,940.94 | -1,936,641.03 | -502,007.48 |
| 扣除非经常损益后的净利润 | -177,153,721.14 | -89,352,213.05 | -408,954,819.81 | -285,984,959.36 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.29 | -0.15 | -0.68 | -0.48 |
| (二)稀释每股收益 | -0.28 | -0.14 | -0.65 | -0.46 |
| 八、其他综合收益 | 824,831.05 | -52,203.72 | -5,208,757.06 | -2,291,721.15 |
| 归属于母公司股东的其他综合收益 | 828,171.66 | -50,180.14 | -5,162,799.98 | -2,230,279.48 |
| 九、综合收益总额 | -169,187,383.26 | -86,393,882.94 | -391,208,816.73 | -273,633,792.09 |
| 归属于母公司股东的综合收益总额 | -161,385,875.95 | -83,580,918.42 | -389,226,218.62 | -273,070,342.94 |
| 归属于少数股东的综合收益总额 | -7,801,507.31 | -2,812,964.52 | -1,982,598.11 | -563,449.15 |
| 公告日期 | 2025-08-29 | 2025-04-30 | 2025-04-19 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |